Blood thinner, antidiabetic drug mix increases hospitalizations

December 07, 2015

A blood thinner known for serious drug interactions is linked to increased hospitalizations for falls, altered mental state and insulin shock for Medicare patients who also take some diabetes drugs, according to a new study.

Forty percent of the estimated 100,000 older Americans hospitalized each year due to adverse drug events are for reactions to the common blood thinner warfarin and to anti-diabetic drugs, including glipizide or glimepiride, also known as 'sulfonylureas.'

Clinical references warn doctors of a potential interaction between these drugs, but evidence of it has been thin, said the study's lead author John Romley, an associate professor at the USC Schaeffer Center for Health Policy and Economics and USC Price School of Public Policy.

"Until now, no one had really studied the interactions between them," he said.

When taken with one of those anti-diabetic drugs, warfarin can intensify their effects and send blood sugar levels crashing. Patients experiencing hypoglycemia may seem drunk, lightheaded and confused, and are at risk of falling.

Hospital admission or emergency-room visits are nearly 22 percent higher for Medicare patients taking warfarin with glipizide, or with glimepiride, the researchers found. (That figure has been adjusted to account for factors such as patient health status.)

The study published in The BMJ on Dec. 7 showed hospitalizations for hypoglycemia were rare but more common for falls. The researchers said evidence of the drug-to-drug interaction was clear.

"The take-home message is simply that an interaction can occur that has clinical significance, so providers need to be aware in order to prevent a low blood sugar issue from occurring," said co-author Anne Peters, a professor at the Keck School of Medicine of USC.

"Sometimes this means having the patient monitor their blood sugar levels more often," said Peters, who directs the Comprehensive Diabetes Center at Roybal Community Medical Center and directs the Westside Center for Diabetes. "There are many ways to deal with the issue if one is forewarned."

Doctors aware of the drug interactions could save lives, reduce harm -- and save the health care system millions of dollars. Hospital visits for hypoglycemia average out to about $20,500 per stay, according to the study. Treatment of fall-related medical conditions also cost an estimated $12,300 per stay.

Study details

Within a random sample of 465,918 Medicare beneficiaries, researchers found that 2,111 patients taking warfarin and one of the anti-diabetic drugs were hospitalized or visited the emergency room for hypoglycemia. Seventy-eight of those patients ended up at the hospital multiple times.

The trend was more pronounced among men 65 to 74 years old, the researchers said.

The study had some limitations: Researchers did not directly measure drug use; they used prescription fills as a proxy. In addition, their findings could be confounded by some unmeasured characteristics in patients that may be connected to warfarin use or a risk for hypoglycemia.

Extra precaution

Pharmacists don't need to change patient instructions, said Bradley Williams, a study co-author and professor of clinical pharmacy and clinical gerontology at the USC School of Pharmacy and USC Davis School of Gerontology.

"What it does require is for pharmacists and other clinicians to be more vigilant when a sulfonylurea is added to a regiment that includes warfarin, as well as when a patient who is taking both has a change in their medical status," Williams said.

He added: "I think additional research into the potential interactions between medications for diabetes and warfarin, as well as other drugs that affect blood clotting, is warranted because of the potential consequences of excessive bleeding."
-end-
The study's other co-authors were: Dana Goldman, the chair and director of the Schaeffer Center who also is a professor at the School of Pharmacy and the Price School of Public Policy; Cynthia Gong, a Schaeffer Center post-doctoral student; and Anupam Jena, an associate professor of health care policy and medicine at Harvard Medical School and an assistant physician in the Department of Medicine at Massachusetts General Hospital.

University of Southern California

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.